Epidermal Growth Factor
6
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Study to Evaluate the Safety of ATR-04
Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.
Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines
Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors
Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors